

## MS Alkeon UCITS Fund

A Sub-fund of Fundlogic Alternatives plc, an Irish UCITS Fund

## Fund Objective and Investment Strategy

Alkeon's investment philosophy is centered on performing deep fundamental analysis of individual company stocks and identifying growth cycles that are largely independent of the economic cycles. The portfolio's long investments emphasize positions in growth companies with improving fundamentals, strong balance sheets and free cash flows, and superior competitive positions. On the short side, Alkeon maintains an active alpha-seeking stock specific portfolio by establishing short positions in low quality businesses facing long term challenges such as unstable and weak business models, deteriorating fundamentals, and declining profitability metrics. Core to the Alkeon approach is the concept that innovation often creates opportunities for growth, while at the same time it can destroy value – this leads to attractive long and short investment opportunities with the potential to create alpha on both sides of the portfolio.

Alkeon employs a bottom-up, fundamentally driven, research-intensive approach to investing, the core of which includes extensive analysis of business drivers and detailed modeling of projected earnings, executive-level understanding of industry competitive dynamics, market share shifts, profitability trends and growth rates, as well as extensive communications with industry leaders and executives globally. Alkeon has a mandate to pursue superior growth opportunities globally, including emerging markets.

## Investment Management

Established in 2002, Alkeon Capital Management, LLC. is a limited liability company registered as an investment advisor with the U.S. Securities and Exchange Commission. The company was founded by Panayotis "Takis" Sparaggis who has more than 20 years of experience in asset management.

Alkeon Capital Management, LLC. manages approximately \$5.0 Bn of assets under management through 6 different strategies. Alkeon has 36 employees and has offices in New York, Boston and Hong Kong.

Historical Monthly Returns <sup>(1)</sup>

		Jan	Feb	Mar	Apr	May	Jun	Jul <sup>(2)</sup>	Aug	Sept	Oct	Nov	Dec	YTD <sup>(2)</sup>
2011	Alkeon - Share I-USD	-	-	-	-	-	-	-1.46%	-4.12%	-3.75%	12.28%	-3.79%	-5.45%	-7.12%
	MSCI World Index	-	-	-	-	-	-	-3.16%	-7.26%	-8.85%	13.60%	-5.55%	-0.17%	-12.32%
2012	Alkeon - Share I-USD	5.79%	5.15%	3.68%	-0.75%	-3.99%	1.25%	0.93%	2.12%	-0.08%	-2.46%	0.82%	-0.34%	12.33%
	MSCI World Index	4.93%	4.66%	1.02%	-1.37%	-8.99%	4.93%	1.20%	2.29%	2.52%	-0.76%	1.07%	1.75%	13.18%
2013	Alkeon - Share I-USD	2.34%	-0.20%	0.85%	-1.06%	2.24%	-1.30%	4.29%	-2.34%	4.09%	1.79%	2.11%	1.70%	15.25%
	MSCI World Index	5.00%	-0.02%	2.10%	2.89%	-0.29%	-2.61%	5.19%	-2.33%	4.82%	3.83%	1.59%	2.01%	24.10%
2014	Alkeon - Share I-USD	-2.83%	3.62%	-3.59%	-2.21%	2.40%	1.55%	-1.33%	2.11%	-1.57%	2.62%	1.76%	-1.10%	1.10%
	MSCI World Index	-3.77%	4.81%	-0.09%	0.83%	1.63%	1.65%	-1.67%	2.00%	-2.88%	0.57%	1.84%	-1.71%	2.93%
2015	Alkeon - Share I-USD	-2.76%	5.80%	-0.97%	-0.15%	1.02%	-0.75%	1.28%	-5.02%	-6.12%	7.69%	-0.11%	-2.15%	-3.06%
	MSCI World Index	-1.88%	5.68%	-1.81%	2.16%	0.05%	-2.46%	1.73%	-6.81%	-3.86%	7.83%	-0.67%	-1.87%	-2.74%
2016	Alkeon - Share I-USD	-6.79%	-1.81%	2.87%	-1.57%	5.42%	-2.06%	4.30%	2.26%	0.50%	-0.82%	-2.26%	-2.48%	-3.04%
	MSCI World Index	-6.05%	-0.96%	6.52%	1.38%	0.23%	-1.28%	4.15%	-0.13%	0.36%	-2.01%	1.25%	2.29%	5.32%

Source: Morgan Stanley / Northern Trust. The above figures refer to the past. Past performance is not a reliable indicator of future results. Performance is quoted net of fees and based on unaudited figures.

Investment Manager Commentary <sup>(3)</sup>

December offered positive results to global equities. Alkeon UCITS returned -2.48%. Results were positive in financials, consumer staples, healthcare and utilities and negative in technology, industrials and consumer discretionary. Portfolio performance was positive in South Korea and the UK and negative in the US, Japan and China. Our long and short positions underperformed.

We see a strong set of investment opportunities for individual stocks and the portfolio overall in the current environment. At month- and year-end, the forward-year weighted average EV/EBITDA (gross cash flow) multiple for our portfolio was approximately 8.8 times<sup>6</sup>, which represents a notable discount to the market (the forward-year EV/EBITDA multiple for the MSCI World Index, is approximately 9.8 times (source Bloomberg)) despite the portfolio's superior growth rate.

As we enter 2017, our thoughts can be summarized in three key points. One, we currently believe classic growth stocks are significantly undervalued relative to the market. Two, our portfolio has experienced significant multiple contraction. And three, based on our research, we see clear, upward pressures on both employment gains and wages, which, combined with an expansionary set of proposed policies by the new administration (e.g., tax cuts, infrastructure spending and corporate tax repatriation), are likely to drive inflation and accelerate economic growth.


1. Index information is included for illustration purposes only and is not intended to imply that the portfolio was similar to any index either in composition or element of risk. The Index performance is adjusted to match MS Alkeon UCITS Fund valuation period.

2. For 2011, July 2011 and YTD performances are from 22nd July, 2011.

3. Information sourced from Alkeon Capital Management, LLC and mirrors the opinion and expectations of Alkeon only. It is not agreed with Morgan Stanley and may not mirror Morgan Stanley's views.

## Fund Characteristics

Inception Date	22-Jul-11
Total Assets (USD)	\$69 MM
Base Currency	USD
Domicile	Ireland
Passporting Status (registered in)	UK, Spain, Italy, Germany, France, Luxembourg, Switzerland
Also permitted for sale to certain investors in	Singapore
Legal Structure	An Open-Ended Investment Company (OEIC)
Dealing Day	Weekly. Every Friday (except legal public holidays in the UK and Ireland and days on which stock markets in London are closed)
Subscription/Redemption notice	12 midday Irish time, 5 business days prior to the relevant dealing day
Settlement	Subscription: Dealing Day +3 Redemption: Dealing Day +5
Currency Classes Available	USD / EUR / CHF / GBP
Investment Manager	Alkeon Capital Management, LLC.
Promoter & Distributor	Morgan Stanley & Co International plc
Custodian	Northern Trust Fiduciary Services (Ireland) Ltd
Administrator	Northern Trust International Fund Administration Services (Ireland) Ltd
Auditor	Ernst & Young

Performance <sup>(1)</sup>

Sources: Fund - Morgan Stanley, Northern Trust / MSCI World (MXWO Index) - Bloomberg.  
The above figures refer to the past. Past performance is not a reliable indicator of future results.

Stocks generally do well at the initial stages of an inflation uplift period, although low-volatility stocks and interest-rate sensitive sectors tend to underperform.

Following the results of the US election, strong performance in cyclical and financial stocks have left growth stocks significantly undervalued relative to the market, in our view. As we have described in recent communications, growth stocks that typically trade at a P/E premium to the market have instead been trading at their largest discount to the market in nearly 30 years.

As a result, we believe the recent underperformance in growth stocks has painted a picture of notable undervaluation in classic, secular growth compounders in general and in our portfolio in particular. We therefore regard the current risk/reward proposition for our portfolio as compelling in both relative and absolute value terms, and we remain equally excited about the long and short investment opportunity sets.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.

# MS Alkeon UCITS Fund

## Risk Metrics <sup>(5)</sup>


Exposure and Risk Summary	
	% of NAV
Long Exposure	135%
Short Exposure	-47%
Gross Exposure	182%
Net Exposure	88%
Annualised Volatility <sup>(6)</sup>	12.6%
Relative VaR <sup>(8)</sup>	1.21

Source: Morgan Stanley

Position Summary	
	Number of Positions
No. of Long	37
No. of Short	25
% of NAV	
Top 5 Longs	23.2%
Top 5 Shorts	-16.2%


Source: Morgan Stanley

## Market Cap Analysis (Equities) <sup>(4)(7)</sup>




Source: Morgan Stanley

## Sector Analysis <sup>(5)</sup>



Source: Morgan Stanley

## Geographic Analysis <sup>(5)</sup>



Source: Morgan Stanley

4. Month-end data used. Exposure is delta adjusted, excludes market hedges

5. Month-end data used. Exposure is delta adjusted, includes market hedges

6. Indicative values as insufficient data points for statistical calculations. The volatility is computed as the standard deviation of the daily returns

7. Mega Cap ( $\geq 20$  Bn); Large Cap ( $\geq 5$  Bn,  $< 20$  Bn); Mid Cap ( $\geq 1$  Bn,  $< 5$  Bn); Small Cap ( $> 0$ ,  $< 1$  Bn)

8. Var 99% - 20 days computed against the MSCI WORLD as benchmark.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.

## MS Alkeon UCITS Fund

## Fund Share Class Details

	Share Class			Performance				Identifiers			Fees		
	Ccy	Min Inv	Launch Date	NAV	MTD	YTD	LTD	ISIN	BBG	SEDOL	Mgmt	Perf.	TER <sup>(10)</sup>
Class I	USD	1,000,000	22-Jul-11	1142.44	-2.48%	-3.04%	14.24%	IE00B66Q8211	FAMSAIU	B66Q821	2.0%	20%	2.37%
Class I	EUR	1,000,000	22-Jul-11	1104.45	-2.68%	-4.19%	10.45%	IE00B68CVQ25	FAMSAIE	B68CVQ2	2.0%	20%	2.37%
Class I	CHF	1,000,000	22-Jul-11	1101.90	-2.65%	-4.38%	10.19%	IE00B3Q2LM98	FAMSAIC	B3Q2LM9	2.0%	20%	2.37%
Class I	GBP	1,000,000	21-Sep-12	1066.83	-2.43%	-3.07%	6.68%	IE00B5ZPSL16	FAMSAIG	B5ZPSL1	2.0%	20%	2.37%
Class C <sup>(9)</sup>	EUR	1,000,000	02-Sep-11	1239.63	-2.60%	-3.21%	23.96%	IE00B5N8Q634	FAMSACE	B5N8Q63	1.0%	20%	1.37%
Class A	USD	10,000	25-Nov-11	1176.49	-2.52%	-3.53%	17.65%	IE00B6126197	FAMSAAU	-	2.5%	20%	2.87%
Class A	EUR	10,000	02-Mar-12	1047.46	-2.72%	-4.67%	4.75%	IE00B6874242	FAMSAAE	-	2.5%	20%	2.87%
Class A	CHF	10,000	10-Feb-12	1054.69	-2.69%	-4.86%	5.47%	IE00B6047G88	FAMSAAC	-	2.5%	20%	2.87%
Class A	GBP	10,000	15-Feb-13	1038.47	-2.47%	-3.56%	3.85%	IE00B3LDKT75	FAMSAAG	B3LDKT7	2.5%	20%	2.87%
Class P	USD	250,000	15-Feb-13	1059.96	-2.48%	-3.04%	6.00%	IE00B9492984	FAMSPUS	B949298	2.0%	20%	2.37%
Class P	EUR	250,000	28-Jun-13	1048.79	-2.68%	-4.18%	4.88%	IE00B948FX09	FAMSPEU	B948FX0	2.0%	20%	2.37%
Class P	GBP	250,000	19-Jul-13	1019.17	-2.43%	-3.06%	1.92%	IE00B945VM21	FAMSPBP	B945VM2	2.0%	20%	2.37%

Source: Morgan Stanley. NAV are computed by Northern Trust

9. Class C Shares (EUR/ USD/ GBP) are initial investor share classes and therefore it is expected that such Shares will only be available for subscription until such time as the net assets of the sub-fund reach \$50 MM, or such other amount as may be determined by the Directors from time to time in their absolute discretion

10. Total Expense Ratio includes Management Fees and Promoter fees. For share classes launched before 31-Jul-14, the TER is based on the expenses for the year ending 31-Jul-14. This figure may vary from year to year.

## Important Information

This document has been prepared by Morgan Stanley & Co International plc as a marketing document to inform Professional Investors and Eligible Counterparts about certain matters concerning the Fund. It has been prepared solely for informational purposes and does not seek to make any recommendation to buy or sell any particular security (including Shares in the Fund) or to adopt any specific investment strategy. Any use of this document by a financial intermediary is restricted to clients for whom the information in this document and an investment in Shares of the Fund has been considered to be suitable by that financial intermediary in view of that client's situation and purpose, subject always to the applicable regulatory standard. If such a client considers an investment in Shares of the Fund, she/he should always ensure that she/he has satisfied herself/himself that she/he has been properly advised by that financial intermediary about the suitability of an investment.

This financial promotion has been issued and approved in the UK by Morgan Stanley & Co International plc, 25 Cabot Square, Canary Wharf, London E14 4QA, authorized and regulated by the Financial Conduct Authority, for distribution to Professional Clients or Eligible Counterparties only and must not be relied upon or acted upon by Retail Clients (each as defined in the UK Financial Conduct Authority's rules). All of the information contained in this document relating to Alkeon Capital Management, LLC. (the "Alkeon Information") is communicated by Alkeon Capital Management, LLC. located at 350 Madison Avenue, 9th Floor, New York, NY 10017, USA, registered as an investment adviser with the US Securities and Exchange Commission. While the board of the Fund has overall responsibility for monitoring of the investment objective, policy and performance of the Fund, Morgan Stanley & Co International plc disclaims any and all liability relating to the Alkeon Information, including, without limitation, any express or implied representations or warranties for statements or errors contained in, and omissions from, the Alkeon Information.

Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, Key Investor Information Document, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge at the address above. The Offering Documents contain material information not contained herein. In particular, the Prospectus contains details relating to the terms of investment and information regarding investment risks and conflicts of interest. Any representation to the contrary is not permitted. In the event of such offering, the information in this document will be superseded, amended and/or supplemented in its entirety by the Prospectus. You should not rely solely on the information contained herein, including but not limited to the Alkeon Information, but should carefully read, the Offering Documents before making any investment decision.

The material contained herein has not been based on a consideration of any individual client circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley & Co International plc. It is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

No representation or warranty can be given with respect to the accuracy or completeness of the information, or with respect to the terms of any future offer of transactions conforming to the terms hereof. We do not undertake to update this information. Certain assumptions may have been made in the analysis that resulted in any information and returns/results detailed herein. No representation is made that any results/returns indicated would be achieved or that all assumptions in achieving these returns have been considered or stated. Changes to the assumptions may have a material impact on any results/returns detailed. Morgan Stanley and its affiliates disclaim any and all liability relating to this information, including without limitation any express or implied representations or warranties for statements contained in, and omissions from, this information.

Additional information concerning the portfolio may be available upon request from the investment manager.

Although this report has been prepared using sources, models and data that Morgan Stanley ("MS") believes to be reasonably reliable, its accuracy, completeness or suitability cannot be guaranteed. Therefore, this information is supplied on an "AS IS" basis, and NO WARRANTY IS MADE AS TO ITS ACCURACY, COMPLETENESS, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto.

All information contained herein is proprietary and is protected under copyright law.

The investment manager to the Fund may from time to time, at its sole discretion and out of its own resources, decide to rebate to Shareholders part or all of its investment management fee and/or performance fee. Any such rebates may be applied by issuing additional shares to shareholders or in cash. In addition to the information disclosed in the periodic reports of FundLogic Alternatives plc (the "Company"), the Company may, from time to time, make available to investors portfolio holdings and portfolio-related information in respect of one or more of the sub-funds including the Fund. Any such information will be available to all investors in the relevant sub-fund on request. Any such information will only be provided on a historical basis and after the relevant dealing day to which the information relates.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.

## ADDITIONAL ALKEON DISCLOSURES:

The investment strategy of the Sub-Fund for which Alkeon acts as Investment Manager involves substantial risks. No guarantee or representation is made that the investment program of the Sub-Fund will be successful.

The Alkeon Information contained herein has been obtained by Alkeon from sources deemed to be reliable, but is subject to unintentional errors, omissions and changes without notice, and is not warranted by Alkeon as to its accuracy or completeness. It is the responsibility of the recipient to independently confirm the accuracy and completeness of the Alkeon Information. Alkeon does not assume any duty to update any Alkeon Information in this document for subsequent changes of any kind.

Alkeon has been appointed as the investment manager of the MS Alkeon UCITS Fund (the "Alkeon Fund") by the board of the FundLogic Alternatives Plc (the "OEIC"). Morgan Stanley & Co International plc and its affiliates (Morgan Stanley) do not have a right to direct the investment of the Alkeon Fund. The performance of the Alkeon Fund will be dependent on the proper functioning of the internal management and systems of Alkeon and the other service providers. The board of the OEIC will generally not have the opportunity to evaluate the specific investments made by Alkeon before they are made.

Accordingly, no person should invest in the Alkeon Fund unless willing to entrust all aspects of selection and management of the Alkeon Fund's investments to Alkeon. Morgan Stanley does not accept any liability for any losses caused by the actions or inaction of Alkeon in connection with the performance of its management duties to the OEIC. The content hereof is intended for general information purposes only. The information contained herein is limited and is not intended to provide a representation of the merits or risks associated with an investment in any of the funds and accounts (the "Alkeon Funds") managed by Alkeon Capital Management, LLC or its affiliates ("Alkeon").

## Risk Warning:

Past performance is not a guarantee of future performance. The value of the investments and the income from them can go down as well as up and an investor may not get back the amount invested. There can be no assurance that the Fund will achieve its investment objectives.

Investments may be in a variety of currencies and therefore changes in rates of exchange between currencies may cause the value of investments to decrease or increase. Furthermore, the value of investments may be adversely affected by fluctuations in exchange rates between the investor's reference currency and the base currency of the investments.

Investments in derivative instruments carry certain inherent risks such as the risk of counter party default and before investing you should ensure you fully understand these risks. Use of leverage may also magnify losses as well as gains to the extent that leverage is employed.

These investments are designed for investors who understand and are willing to accept these risks. Performance may be volatile, and an investor could lose all or a substantial portion of his or her investment.

## Selling Restrictions:

The Fund may only be offered and distributed to investors in accordance with all relevant local laws and regulations. The distribution of this presentation and the offering or purchase of interests in the Fund may be restricted in certain countries. This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations. It is the responsibility of any persons in possession of this document and any persons wishing to purchase interests in the Fund to inform themselves of, and to observe, all applicable laws and regulations of any relevant country.

For Investors in Hong Kong: This document is issued by Morgan Stanley Asia Limited ("Morgan Stanley") and has not been reviewed by the Securities and Futures Commission of Hong Kong. This document is only intended for and will only be distributed to persons that are professional investors as defined under the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong) and its subsidiary legislation as amended from time to time ("Professional Investors") and may not be circulated to the general public in Hong Kong. This Fund has not been authorised by the Securities and Futures Commission and may only be sold to Professional Investors. Applications for shares in the MS ALKEON UCITS Fund should not be made without first consulting the current Prospectus, Key Investor Information Document, Annual Report and Semi-Annual Report ("Offering Documents") of the Fund.

This document has been prepared as information for Professional Investors in Hong Kong and it is not a recommendation to buy or sell any particular security or to adopt any investment strategy. Investors should exercise caution and seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley, and are based on matters as they exist as of the date of preparation and not as of any future date, and will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date hereof. No representation or warranty is given with respect to the accuracy or completeness of the information herein. This document is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation.

For Investors in Singapore: This material is being disseminated in Singapore by Morgan Stanley Asia (Singapore) Pte. The Fund is not authorised or recognised by the Monetary Authority of Singapore ("Authority") and shares in the Funds ("Shares") are not allowed to be offered to the Singapore retail public. This material which relates to the offer of Shares in the Funds is not a prospectus as defined in the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should consider carefully whether the investment is suitable for you.

This material has not been registered as a prospectus by the Authority, and the offer of the Shares is made pursuant to the exemptions under Sections 304 and 305 of the SFA. Accordingly, the Shares may not be offered or sold, nor may the Shares be the subject of an invitation for subscription or purchase, nor may this material or any other document or material in connection with the offer or sale, or invitation for subscription or purchase of the Shares be circulated or distributed, whether directly or indirectly, to any person in Singapore other than under exemptions provided in the SFA for offers made (a) to an institutional investor (as defined in Section 4A of the SFA) pursuant to Section 304 of the SFA, (b) to a relevant person (as defined in Section 305(5) of the SFA), or any person pursuant to an offer referred to in Section 305(2) of the SFA, and in accordance with the conditions specified in Section 305 of the SFA or (c) otherwise pursuant to, and in accordance with, the conditions of any other applicable provision of the SFA.

Where the Shares are acquired by persons who are relevant persons specified in Section 305A of the SFA, namely:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within 6 months after that corporation or that trust has acquired the Shares pursuant to an offer made under Section 305 of the SFA except:

- (1) to an institutional investor or to a relevant person as defined in Section 305(5) of the SFA, or which arises from an offer referred to in Section 275(1A) of the SFA (in the case of that corporation) or which arises from an offer that is made on terms that such rights or interest in that trust are acquired at a consideration of not less than S\$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets (in the case of that trust);
- (2) where no consideration is or will be given for the transfer; or
- (3) where the transfer is by operation of law.

Any offering of the Shares in Singapore would be through Morgan Stanley Asia (Singapore) Pte., an entity regulated by the Authority.

For Investors in Australia: This document is not an offer document under Chapter 6D of the Australian Corporations Act 2001, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of an offer document under Chapter 6D of the Corporations Act. Accordingly: (i) the offer of shares under this document is only being made in Australia to "Sophisticated Investors" within the meaning of Section 708(8) of the Corporations Act or "Professional Investors" within the meaning of Section 708(11) of the Australian Corporations Act, in each case who are "wholesale clients" for the purposes of section 761G(7) of the Corporations Act; (ii) this document is being made available in Australia only to such persons; and (iii) each applicant for shares in Australia represents that the applicant is such a person and, unless permitted under the Corporations Act, agrees not to sell or offer for sale within Australia any of the shares issued to the applicant within 12 months after their issue to the applicant under this document. Offers and issues of shares under this document in Australia are being made pursuant to an arrangement with Morgan Stanley Australia Limited.

For Investors in Switzerland: The representative and paying agent of FundLogic Alternatives plc, an Irish UCITS fund, in Switzerland is BNP PARIBAS Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich. The prospectus and the key investor information documents for Switzerland, the articles as well as the annual and semi-annual reports of FundLogic Alternatives plc may be obtained free of charge from the representative in Switzerland.

This communication or any portion hereof, may not be reprinted, resold or redistributed without the prior written consent of Morgan Stanley.  
Copyright © by Morgan Stanley 2016, all rights reserved.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.